Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
<p><strong>Background:</strong> Baricitinib (Bari) is an oral, selective and reversible Janus kinase 1 and 2 inhibitor approved for the treatment of adults with active RA. In addition to long-term safety which has been disclosed previously with data up to 7 years [1], an important...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Conference item |
| Idioma: | English |
| Publicado: |
BMJ Publishing Group
2020
|